Clinical Research Institute of Michigan – Shores Rheumatology
Primary Coordinator: Amelia Paliewicz 586-598-3329 X 201
- Indication: COVID-19
- Enrollment Status: Enrollment Closed
- Protocol: AZ D7000C00001 “Supernova”
- Drug: AZD5156
- Sponsor: AstraZeneca
- Description: A Phase I/III Randomized, Double-blind Study to Evaluate the Safety and Neutralizing Activity of AZD5156 for Pre-exposure Prophylaxis of COVID-19 in Participants with Conditions Causing Immune Impairment
Clinical Research Institute of Michigan – Shores Rheumatology
Primary Coordinator: Amelia Paliewicz 586-598-3329 X 201
- Indication: Cutaneous Lupus Erythematosus
- Enrollment Status: Open
- Protocol: IMVT-1402-2701
- Drug: IMVT-1402
- Sponsor: Immunovant
- Description: A Phase 2b, Randomized, Double-blind, Placebo-controlled Study to Assess the Safety, Tolerability, and Efficacy of IMVT-1402 in Participants with Active Subacute Cutaneous Lupus Erythematosus (SCLE) and/or Chronic Cutaneous Lupus Erythematosus (CCLE) With or Without Systemic Manifestations
Clinical Research Institute of Michigan – Shores Rheumatology
Primary Coordinator: Amelia Paliewicz 586-598-3329 X 201
- Indication: Gout
- Enrollment Status: Enrollment Closed
- Protocol: HZNP-KRY-409
- Drug: KRYSTEXXA® (pegloticase)
- Sponsor: Horizon/Amgen
- Description: A Phase 4, Randomized, Double-blind, Multicenter Non-inferiority Trial Evaluating the Efficacy and Safety of Intravenous KRYSTEXXA® (pegloticase) Administered Every 4 Weeks Compared with KRYSTEXXA Administered Every 2 Weeks with Co-administration of Weekly Doses of Methotrexate, Followed by an Open-label Extension, in Participants with Uncontrolled Refractory Gout (FORWARD II)
Clinical Research Institute of Michigan – Shores Rheumatology
Primary Coordinator: Amelia Paliewicz 586-598-3329 X 201
- Indication: Gout
- Enrollment Status: Pre-Enrollment
- Protocol: FYU-981-CRYS-301
- Drug: Dotinurad
- Sponsor: Crystalys
- Description: A Phase 3, Randomized, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of Dotinurad Compared With Allopurinol in Adult Participants With Hyperuricemia Associated With Gout
Clinical Research Institute of Michigan – Shores Rheumatology
Primary Coordinator: Amelia Paliewicz 586-598-3329 X 201
- Indication: Gout
- Enrollment Status: Pre-Enrollment
- Protocol: FYU-981-CRYS-302
- Drug: Dotinurad
- Sponsor: Crystalys
- Description: A Phase 3, Randomized, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of Dotinurad Compared With Allopurinol in Adult Participants With Tophaceous Gout
